SecBot SecBot
PRESS-RELEASE ·Filed Jul 1, 2026

SNDX

Syndax Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago WireGlobeNewswire
Press release · Activist
Actionable Insight • Neutral

No actionable signal, this is standard new-hire equity compensation for a commercial-stage biotech. Monitor upcoming earnings or pipeline catalysts (revumenib, entinostat) for real share-moving events.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$21.82
T+0 close · Jul 1, 2026 · via day close
Latest settled
−16.59%
T+60 · $18.20
Vs SPY
−20.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 2 $21.82entry
  2. T+1 · 4mo ago +1.19%α +0.32% · $22.08
  3. T+5 · 4mo ago +13.84%α +12.91% · $24.84
  4. T+20 · 4mo ago −10.72%α −10.31% · $19.48
  5. T+60 · 7w ago −16.59%α −20.16% · $18.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Syndax granted 250,700 performance-based stock options to 8 new hires under its 2023 Inducement Plan, with four-year graded vesting. This is routine new-hire inducement equity for a commercial-stage biotech, no material financial impact.

Key Facts

  • 250,700 shares of common stock granted as inducement awards to 8 new employees
  • Awards are stock options under the 2023 Inducement Plan
  • Vesting: 25% at one-year anniversary, then monthly over 36 months (total 4-year vest)
  • Grant date: July 1, 2026; vesting commencement date and exercise price not stated

Financial Impact

Routine equity grant, no cash impact; ~0.3% dilution of ~83M basic shares outstanding (not stated, est.)

dilution

Risk Factors

  • None from this filing, new-hire inducement grants are routine

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3320972

Track record

16 reports on SNDX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago 3 Neutral 1/10 Entry $9.45 Now $9.13 −3.39% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 2/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
  4. Nov 2, 202614d ago 8-K Neutral 5/10 No price data
  5. Nov 2, 202614d ago Press Release Neutral 2/10 No price data
  6. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $14.29 Now $9.13 −36.11% settles Feb 1
  7. Oct 29, 202618d ago 144 Neutral 2/10 Entry $13.65 Now $9.13 −33.11% settles Jan 28
  8. Jul 14, 202617w ago 8-K Bullish 7/10 Entry $24.13 to $17.03 Now $9.13 −62.16% ▼ −29.42% −32.80% vs SPY
  9. Jul 1, 202619w ago Press Release Neutral 2/10 Viewing Entry $21.82 to $18.20 Now $9.13 −58.16% ▼ −16.59% −20.16% vs SPY
  10. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $17.91 to $20.56 Now $9.13 −49.02% ▲ +14.80% +10.40% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 7h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 1, 2026